Enveric Secures New U.S. Patent Allowance for Non-Hallucinogenic PTSD Drug Candidates

Key Points

• Enveric Biosciences received a Notice of Allowance from the U.S. Patent and Trademark Office for compounds in its EVM401 drug-candidate series.
• The allowance is the third U.S. patent allowance for Enveric’s EVM401 program.
• The compounds are proprietary mescaline-derived molecules designed to promote neuroplasticity without hallucinogenic effects.
• Enveric is evaluating the series for potential use in post-traumatic stress disorder, or PTSD, and other psychiatric and neurological conditions.
• The patent has not yet been issued, but Enveric said the allowed claims are expected to strengthen its intellectual-property portfolio.

Enveric Biosciences (NASDAQ: ENVB) said it has received a U.S. Patent and Trademark Office Notice of Allowance for a patent application covering compounds in its EVM401 Series. The program consists of experimental, non-hallucinogenic mescaline-derived compounds intended to promote neuroplasticity for potential psychiatric and neurological treatments.

New Patent Allowance Covers Proprietary EVM401 Drug Compounds

The patent application is titled “Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives.”

According to Enveric, the allowance is the third U.S. patent allowance tied to the EVM401 Series. Once issued, the patent is expected to include composition-of-matter claims covering proprietary methylone-inspired benzodioxole analogs.

Composition-of-matter protection can be important for drug developers because it may protect the specific chemical compounds themselves, rather than only a particular use or formulation.

EVM401 Compounds Aim to Promote Neuroplasticity Without Hallucinations

Enveric described EVM401 as a group of non-hallucinogenic neuroplastogens. Neuroplasticity refers to the brain’s ability to adapt, change, and form or reorganize connections.

The company said the compounds are designed to retain certain features associated with methylone while introducing structural changes intended to reduce or eliminate hallucinogenic effects.

Methylone’s chemical structure is in the public domain and does not have composition-of-matter patent protection, according to Enveric. The company said its EVM401 compounds contain different benzodioxole-ring modifications intended to distinguish them from known molecules.

Enveric Targets PTSD and Other Psychiatric Conditions

Enveric said its EVM401 compounds could potentially be developed for PTSD and other psychiatric or neurological disorders.

The company stated that its chemical modifications may increase lipophilicity, help compounds cross the blood-brain barrier, and improve metabolic stability. Enveric said these characteristics could support oral administration while maintaining a neuroplasticity-promoting profile.

The compounds remain in development and have not been approved to treat PTSD or any other disorder. The patent allowance does not establish clinical safety or effectiveness.

Patent Portfolio Supports Enveric’s Drug Development Strategy

Enveric said building intellectual property around differentiated neuroplastogenic compounds is a central part of its strategy.

The newly allowed claims could strengthen the company’s ability to develop and potentially commercialize EVM401 candidates that are chemically distinct from methylone. Enveric said the program seeks to preserve potentially beneficial neuroplasticity-related properties while avoiding hallucinogenic effects that can complicate treatment use.